Denali Therapeutics Inc

NASDAQ:DNLI

15.43

+0.47 (+3.14%)

6:49:23 PM EDT: $15.72 +0.29 (+1.88%)

Market Cap (Intraday)	2.20B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$14.15 Million
Adjusted EPS	-$0.70

See more estimates

10-Day MA	$16.30
50-Day MA	$18.96
200-Day MA	$20.71

See more pivots

Denali Therapeutics Inc Stock, NASDAQ:DNLI

161 Oyster Point Boulevard, 2nd Floor, San Francisco, California 94080

United States of America

Phone: +1.615.866.8548

Number of Employees: 445

http://www.denalitherapeutics.com

Description

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.